Orexin Receptor 2 Agonists
Oveporexton restores orexin signaling in narcolepsy type 1 and represents a new therapeutic class.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Size, Share & Industry Analysis, By Type (Narcolepsy Type 1, Narcolepsy Type 2, Secondary Narcolepsy), By Application (Excessive Daytime Sleepiness, Cataplexy, Sleep Paralysis & Hallucinations, Other Symptoms), By Therapeutic Type (Orexin Agonists, Oxybates, Wake-Promoting Agents & Stimulants, Histamine H3 Receptor Antagonists, Antidepressants), By Patient Group (Adults, Adolescents, Pediatric Patients), By Distribution Channel (Specialty Pharmacies, Retail Pharmacies, Hospital Pharmacies, Direct-to-Patient Programs), and Regional Forecast, 2026-2034
The global narcolepsy drug market was valued at USD 4.04 billion in 2025 and is estimated at USD 4.38 billion in 2026. The market is projected to reach USD 8.36 billion by 2034, representing an 8.4% CAGR during 2026–2034.
Narcolepsy is a chronic neurologic sleep disorder characterized by excessive daytime sleepiness and disrupted sleep-wake regulation. Narcolepsy type 1 includes cataplexy and is associated with loss of orexin signaling, while narcolepsy type 2 occurs without cataplexy. Drug treatment historically focused on symptoms such as daytime sleepiness and cataplexy.
The market changed materially in August 2026 when FDA approved ORZEYFUL (oveporexton) for adults with narcolepsy type 1. FDA described it as the first medicine approved to treat the full range of narcolepsy type 1 symptoms and the first to directly restore orexin signaling, creating a new mechanism-based treatment class beyond conventional symptom control.
Established categories remain commercially important. FDA records show current approvals for pitolisant across adult and pediatric narcolepsy and for once-nightly LUMRYZ sodium oxybate in patients aged seven years and older. Jazz Pharmaceuticals reported 11,075 active narcolepsy patients on XYWAV exiting the first quarter of 2026, illustrating the continuing scale of oxybate-based therapy even as orexin agonists enter the market.
Source: FDA ORZEYFUL approval; Takeda ORZEYFUL; NHLBI narcolepsy; FDA WAKIX orphan approvals; FDA LUMRYZ orphan approvals; Jazz Q1 2026.
The study defines the global narcolepsy drug market market by the equipment, application, end-user and technology boundaries listed below. The scope is structured to keep market sizing consistent with the commercial systems and services included in the syndicated study.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD billion |
| By Type | Narcolepsy Type 1; Narcolepsy Type 2; Secondary Narcolepsy |
| By Application | Excessive Daytime Sleepiness; Cataplexy; Sleep Paralysis & Hallucinations; Other Symptoms |
| By Therapeutic Type | Orexin Agonists; Oxybates; Wake-Promoting Agents & Stimulants; Histamine H3 Receptor Antagonists; Antidepressants |
| By Patient Group | Adults; Adolescents; Pediatric Patients |
| By Distribution Channel | Specialty Pharmacies; Retail Pharmacies; Hospital Pharmacies; Direct-to-Patient Programs |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; Germany; France; United Kingdom; Italy; Japan; China; South Korea; Australia; Brazil and other relevant markets |
| Key Market Players | Takeda; Jazz Pharmaceuticals; Avadel Pharmaceuticals; Harmony Biosciences; Axsome Therapeutics; Bioprojet Pharma; Teva Pharmaceutical Industries; Novitium Pharma; generic manufacturers |
The market includes prescription medicines used to treat narcolepsy type 1, narcolepsy type 2 and secondary narcolepsy, including therapies for excessive daytime sleepiness, cataplexy and broader symptom control.
Diagnostic sleep studies, devices for sleep monitoring, idiopathic hypersomnia therapies without a narcolepsy indication and non-prescription sleep products are outside the core revenue boundary.
FDA approval of ORZEYFUL in August 2026 introduced the first approved therapy designed to restore orexin signaling in narcolepsy type 1 rather than only treating individual symptoms.
Jazz reported 11,075 active narcolepsy patients on XYWAV at the end of Q1 2026, demonstrating significant existing demand for nighttime therapy.
FDA records show WAKIX is approved for EDS or cataplexy in patients aged six years and older and LUMRYZ for cataplexy or EDS in patients aged seven years and older.
Narcolepsy symptoms can overlap with insufficient sleep, psychiatric conditions and other sleep disorders, delaying diagnosis and specialist treatment.
FDA listed a first generic pitolisant approval in July 2026, introducing new pricing dynamics in an established histamine H3 receptor antagonist segment.
Source: FDA ORZEYFUL; Jazz Q1 2026; FDA WAKIX; FDA LUMRYZ; FDA first generics.
ORZEYFUL is the first approved orexin receptor 2 agonist, directly addressing the orexin deficiency underlying narcolepsy type 1.
LUMRYZ provides once-nightly sodium oxybate dosing, reducing the need to awaken for a second dose during the night.
Recent WAKIX and LUMRYZ label expansions create larger treated populations in children and adolescents.
FDA’s first generic pitolisant approval in July 2026 introduces lower-cost competition in a differentiated wake-promoting class.
Takeda secured 2026 approvals for ORZEYFUL in China, the United States and Japan, establishing an unusually rapid multi-country launch sequence.
Source: FDA ORZEYFUL; FDA LUMRYZ; FDA first generics; Takeda ORZEYFUL; Takeda Phase 3 publication.
Narcolepsy pharmacotherapy now spans both symptom-directed and mechanism-based treatment.
Oveporexton restores orexin signaling in narcolepsy type 1 and represents a new therapeutic class.
Sodium and mixed-salt oxybates improve cataplexy and daytime symptoms through nighttime treatment.
Wake-promoting therapies primarily target excessive daytime sleepiness.
Histamine H3 receptor antagonism/inverse agonism provides a non-stimulant pathway for EDS and cataplexy.
Source: FDA ORZEYFUL; FDA WAKIX; FDA LUMRYZ.
By type, the market is segmented into narcolepsy type 1, narcolepsy type 2 and secondary narcolepsy. Narcolepsy type 1 is the leading high-value segment.
Type 1 includes cataplexy and orexin deficiency and now has an approved mechanism-based orexin agonist.
Type 2 lacks cataplexy and is treated primarily through wake-promoting and symptom-directed therapy.
Secondary narcolepsy results from another neurologic or structural cause and represents a smaller heterogeneous segment.
Narcolepsy type 1 will remain the most commercially dynamic segment because new orexin-targeted therapy adds premium value to an already intensively treated population.
By application, the market is segmented into excessive daytime sleepiness, cataplexy, sleep paralysis and hallucinations, and other symptoms. Excessive daytime sleepiness represents the broadest treatment application.
EDS affects both major narcolepsy types and is the principal indication for multiple wake-promoting medicines.
Cataplexy is characteristic of narcolepsy type 1 and is treated by oxybates, pitolisant and now orexin-pathway therapy.
These symptoms contribute to total disease burden but are less often the sole driver of drug choice.
Other treatment goals include fragmented nighttime sleep, cognitive impairment and overall daily function.
EDS will remain the broadest application, while cataplexy and full-spectrum symptom control drive higher-value narcolepsy type 1 treatment.
By therapeutic type, the market is segmented into orexin agonists, oxybates, wake-promoting agents and stimulants, histamine H3 receptor antagonists, and antidepressants. Oxybates retain a large installed treatment base while orexin agonists are the fastest-changing segment.
ORZEYFUL created the first approved disease-mechanism class for adult narcolepsy type 1.
XYWAV, XYREM and LUMRYZ support major recurring nighttime-treatment demand.
Modafinil-class agents and stimulants remain widely used for daytime wakefulness.
Pitolisant treats EDS and cataplexy and gained broader pediatric labeling before generic entry.
Selected antidepressants are used off label for cataplexy and REM-related symptoms.
Oxybates will remain a major revenue pool, while orexin agonists should capture the strongest innovation-led growth.
By patient group, the market is segmented into adults, adolescents and pediatric patients. Adults remain the largest treated segment, while pediatric access is expanding.
Most current commercial use occurs in adults across oxybates, wake-promoting medicines, pitolisant and orexin therapy.
Adolescents require long-term symptom management across education, driving and early employment.
WAKIX and LUMRYZ label expansions have broadened treatment options in children from six or seven years of age depending on product.
Adults will remain the largest group, while pediatric and adolescent treatment should grow as diagnosis and approved options expand.
By distribution channel, the market is segmented into specialty pharmacies, retail pharmacies, hospital pharmacies and direct-to-patient programs. Specialty pharmacy is the leading value channel because oxybate and newer therapies often require structured access and support.
Specialty pharmacies manage controlled distribution, reimbursement and patient support for complex narcolepsy medicines.
Retail pharmacies serve wake-promoting agents, stimulants and generic therapies with conventional prescription distribution.
Hospital systems support specialist initiation and inpatient or affiliated outpatient supply.
Manufacturer-linked support and centralized fulfillment help manage rare-disease access and adherence.
Specialty pharmacies will remain the leading high-value channel, while generic entry increases the importance of retail distribution.
Regional demand reflects diagnosis, sleep-specialist access, reimbursement and product launches. North America is the largest market, with Asia-Pacific gaining strategic importance after 2026 orexin approvals.
The United States leads through established oxybate use, broad specialist access and the August 2026 approval of ORZEYFUL.
Europe has broad access to wake-promoting agents, pitolisant and oxybate therapy through specialist sleep centers.
China and Japan approved ORZEYFUL in 2026, giving the region an early role in orexin-agonist commercialization.
Growth depends on diagnosis rates, specialist availability and reimbursement for premium rare-disease medicines.
Treatment remains concentrated in advanced sleep and neurology centers.
Source: FDA ORZEYFUL; Takeda U.S.; NHLBI.
Narcolepsy medicines span controlled substances, rare-disease programs and multiple age-specific indications.
| Framework / Event | Requirement or Development | Commercial Relevance |
|---|---|---|
| ORZEYFUL approval | FDA approved oveporexton on August 5, 2026 for adults with narcolepsy type 1. | Created the first approved orexin-agonist class. |
| WAKIX pediatric expansion | FDA records show WAKIX labeling expanded to EDS or cataplexy in patients six years and older in 2026. | Broadens pediatric treatment. |
| LUMRYZ once-nightly access | FDA orphan records show LUMRYZ approval for patients seven years and older. | Supports once-nightly oxybate competition. |
| Generic pitolisant | FDA listed the first generic pitolisant approval in July 2026. | Introduces price competition in a differentiated class. |
Source: FDA ORZEYFUL; FDA WAKIX; FDA LUMRYZ; FDA generics.
Competition is shifting from symptom-specific classes toward a broader mechanism-based portfolio structure.
ORZEYFUL is the first approved orexin receptor 2 agonist for adult narcolepsy type 1.
Jazz leads with XYWAV/XYREM, while Avadel differentiates with once-nightly LUMRYZ.
These companies compete through non-stimulant, wake-promoting and generic treatment options.
Source: Takeda; Jazz; FDA WAKIX; FDA LUMRYZ.
September 2026: Takeda announced publication of two Phase 3 oveporexton studies in the New England Journal of Medicine after approvals in the United States, China and Japan.
August 2026: FDA approved ORZEYFUL for adults with narcolepsy type 1, creating the first orexin receptor 2 agonist treatment class.
July 2026: FDA listed the first generic pitolisant hydrochloride tablet approval referencing WAKIX.
February 2026: FDA records show WAKIX expanded to treatment of EDS or cataplexy in patients six years of age and older.
Source: Takeda NEJM; FDA ORZEYFUL; FDA generics; FDA WAKIX.
The global narcolepsy drug market market is projected to grow from USD 4.38 billion in 2026 to USD 8.36 billion by 2034, at a 8.4% CAGR during 2026–2034. Growth is expected to accelerate as orexin agonists add disease-mechanism treatment to established oxybate and wake-promoting classes. Pediatric label expansion and generic entry should broaden access, while specialty distribution preserves premium value in newer therapies.
| Forecast Variable | Current Evidence / Starting Point | Expected Effect Through 2034 |
|---|---|---|
| Orexin therapy | A first-in-class mechanism-based treatment entered the market in 2026. | Creates a new growth engine. |
| Oxybate installed base | Large active patient populations support recurring revenue. | Maintains established value. |
| Pediatric expansion | Recent labels cover younger patients. | Broadens the treated population. |
| Generic entry | Pitolisant competition can improve access. | Changes pricing dynamics. |
| Global launches | Orexin approval across the U.S., China and Japan expands geographic reach. | Supports faster international growth. |
The study is structured to support strategy, market-entry assessment, portfolio planning, competitive benchmarking and commercial opportunity analysis across the global narcolepsy drug market landscape.
24LifeScience develops narcolepsy drug market market estimates using a combination of bottom-up and top-down assessment. Bottom-up work reviews relevant manufacturers, product portfolios, geographic presence, installation or utilization patterns, commercial channels and pricing structure. Top-down work evaluates the addressable testing or diagnostic environment, installed capacity, procedure or production demand, replacement and upgrade cycles, and regional access conditions.
Primary research is used to validate market structure, purchasing criteria, technology adoption, competitive positioning and operating constraints where available. Secondary research prioritizes regulators, government and public-health agencies, recognized standards, peer-reviewed or professional evidence, and company filings or official product communications. The analysis combines current FDA approval records, NHLBI disease information and primary company updates from Takeda and Jazz Pharmaceuticals. Market values are presented on a 2025 base-year, 2026 estimate and 2034 forecast framework with the displayed CAGR reconciled to the forecast endpoints.
Forecasts incorporate the 2025 market base, 2026 estimated conditions, technology and regulatory developments, replacement or expansion demand, regional investment, pricing pressure, service requirements and competitive intensity. High-impact assumptions are cross-checked against authoritative evidence before publication.
The market was valued at USD 4.04 billion in 2025 and is estimated at USD 4.38 billion in 2026. It is projected to reach USD 8.36 billion by 2034 at an 8.4% CAGR during 2026–2034.
FDA approved ORZEYFUL, the first orexin receptor 2 agonist and first medicine designed to address the underlying orexin deficiency in adult narcolepsy type 1.
Narcolepsy type 1 is the leading high-value segment because of its broader symptom burden and new mechanism-based therapy.
Excessive daytime sleepiness is the broadest treatment application because it occurs across both major narcolepsy types.
North America is the largest regional market, led by the United States.
Yes. Current FDA records include WAKIX for patients six years and older and LUMRYZ for patients seven years and older.
Oxybates remain a major treatment class for cataplexy and daytime symptoms and support a large established commercial base.
The report profiles Takeda, Jazz Pharmaceuticals, Avadel Pharmaceuticals, Harmony Biosciences, Axsome Therapeutics, Bioprojet and Teva.
The standardized forecast period is 2026–2034, with 2025 as the base year and 2026 as the estimated year.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.